Preventing hepatitis C virus recurrence in liver transplant recipients: A role for adoptive immunotherapy?

Hepatology

Volumn 51, Issue 3, 2010, Pages 1072-1076

  Pawlotsky, Jean Michel ^a   Chevaliez, Stéphane ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HEPATITIS C VIRUS ANTIBODY; INTERLEUKIN 2; OKT 3; PEGINTERFERON ALPHA; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS RNA;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CELL SECRETION; CELL THERAPY; GRAFT RECIPIENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INOCULATION; LIVER CELL; LIVER TRANSPLANTATION; LYMPHOCYTE; MOUSE; NATURAL KILLER T CELL; NONHUMAN; NOTE; PRIORITY JOURNAL; RECURRENT DISEASE; REPLICON; SERUM; VIRUS INHIBITION;

EID: 77950610873     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23579     Document Type: Note

References (14)

1. Roche B, Samuel D. Liver transplantation in viral hepatitis: prevention of recurrence. Best Pract Res Clin Gastroenterol 2008;22:1153-1169.
2. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. HEPATOLOGY 2002;35:680-687.
3. Ohira M, Ishiyama K, Tanaka Y, Doskali M, Igarashi Y, Tashiro H, et al. Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. J Clin Invest 2009;119:3226-3235.
4. Li Y, Zhang T, Ho C, Orange JS, Douglas SD, Ho WZ. Natural killer cells inhibit hepatitis C virus expression. J Leukoc Biol 2004;76: 1171-1179.
5. Wang SH, Huang CX, Ye L, Wang X, Song L, Wang YJ, et al. Natural killer cells suppress full cycle HCV infection of human hepatocytes. J Viral Hepat 2008;15:855-864.
6. Sutlu T, Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med 2009;266:154-181.
7. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-897.
8. Shouval D. Adoptive transfer of immunity to HBV in liver transplant patients: a step forward toward the proof of concept for therapeutic vaccination or a transient immunologic phenomenon? Liver Transpl 2007;13:14-17.
9. Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007; 132:1979-1998.
10. Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-1850.
11. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-1838.
12. Kwo P, Lawitz E, McCone J, Schiff E, Vierling J, Pound D, et al. HCV SPRINT-1 final results: SVR 24 from a phase 2 study of boceprevir plus PegIntron (peginterferon alfa-2b)/ribavirin in treatment-naive subjects with genotype 1 chronic hepatitis C. J Hepatol 2009;50(Suppl. 1):S4.
13. Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, et al. Combination therapy with a nucleoside polymerase (R7128) and protease (R7227/ITMN-191) inhibitor in HCV: safety, pharmacoki-netics, and virologic results from INFORM-1 [Abstract]. HEPATOLOGY 2009;50(4 Suppl.):394A.
14. Pawlotsky JM. Therapeutic implications of hepatitis C virus resistance to antiviral drugs. Ther Adv Gastroenterol 2009;2:205-219.